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Competitions are coming back. Accord-
ing to a 2009 McKinsey Report, prizes 
awarded as incentives for innova-
tion have been increasing over the last 
decade in science, engineering, environ-
mental research, and space exploration 
(http://www.mckinsey.com/App_Media/
Reports/SSO/And_the_winner_is.pdf). 
President Obama recently directed fed-
eral agencies to increase their use of 
incentive prizes as a tool for stimulating 
technological innovation. And in Decem-
ber, program directors at the National 
Institutes of Health (NIH) gathered in a 
closed meeting to discuss incentive prizes 
with the chief of DARPA, the Pentagon’s 
research agency. Among federal agen-
cies that fund research and development, 
DARPA has taken the lead in implement-
ing prizes, starting with its 2004 contest 
to create an unmanned ground vehicle. 
Although neither the NIH nor the National 
Science Foundation yet has legal author-
ity to establish prizes for targeted innova-
tions, they’ve solicited extensive advice 
from the National Academies regarding 
such prizes. The NIH has also consulted 
with leaders at the X Prize Foundation 
(http://www.xprize.org/), a company that 
creates and manages prizes awarded to 
the first team to achieve a specific goal, 
and InnoCentive (http://www.innocentive.
com/), a company that posts challenges 
online for organizations seeking solu-
tions, so that people around the world 
can compete to solve them for a bounty. 
“When you consider that the government 
invests a total of $150 billion in research 
and development, there’s a lot more room 
for experiment in this area,” said Thomas 
Kalil, the Deputy Director for Policy at the 
Office of Science and Technology Policy, 
at the X-Prize-sponsored “incentive2in-
novate” conference held at the United 
Nations in New York (http://i2i.xprize.
org/). The Bill & Melinda Gates Founda-
tion has climbed on board too, recently 
announcing that they would sponsor an 
X Prize to develop a practical and more 
accurate test for tuberculosis.
Incentive prizes also are finding a new 
niche in translational research. At the Har-
vard Catalyst (http://catalyst.harvard.edu/), 
an enterprise for clinical and translational 
medicine founded in 2008, researchers are 
looking into how incentive prizes could be 
used to stimulate innovation in healthcare-
related areas with a series of exploratory 
contests. “We hope these pilot programs 
will create solutions, but we are also using 
them to learn about how cooperation oper-
ates,” says Karim Lakhani at Harvard Busi-
ness School, who is applying his research 
on InnoCentive’s strategy to help design 
Harvard’s competitions.
Later this month, Harvard will launch 
a search for new solutions for type 1 
diabetes by posting a challenge on 
their internal websites as well as on the 
InnoCentive website. Cash prizes will 
be awarded for winning hypotheses or 
concepts. And if all goes according to 
plan, Harvard investigators will then take 
these solutions to the next level by con-
ducting experiments to see if they work. 
In another new pilot competition, profes-
sors from Harvard Medical School, MIT, 
Harvard Business School, and the Lon-
don Business School have teamed up 
with TopCoder (a company that admin-
isters online contests for organizations 
who need software developed) to solicit 
solutions for computational problems in 
genome datasets.
Prizes make sense from a marketing 
perspective. The financer explains what 
they seek and places the risk squarely 
on the competitors, who offer up their 
time, money, and brainpower with no 
guarantee of success. Compare this to 
the grant strategy, in which there’s a fair 
chance that the person receiving fund-
ing will not accomplish their stated goal. 
Peter Diamandis, CEO of the X Prize 
Foundation, describes the benefits of the 
first X Prize of $10 million for launching an 
affordable, privately funded spacecraft 
into space this way: “We leveraged the 
prize purse by ten-fold, it was perfectly 
efficient because we paid on delivery of 
the results, and we brought a new mix 
of investigators into the marketplace that 
did not exist before.”
Why people choose to compete is 
another question. One answer: It’s in 
our nature. InnoCentive’s CEO Dwayne 
Spradlin says, “The number one reason 
why people participate [in competitions] 
is because they want to work on problems 
that matter. If there’s a $10,000 prize, 
that solution is of value to someone.” 
It’s little wonder that the biggest fans 
of prizes flock to the highly publicized 
TED Talks (http://www.ted.com/), a non-
traditional conference devoted broadly 
to “ideas worth spreading.” Attendees 
include scientists, philosophers, celeb-
rities, entrepreneurs, and major inves-
tors (who have bankrolled prizes after 
hearing certain talks). Although incentive 
prizes aren’t awarded at the talks, found-
ers of the X Prize and another incentive 
prize, the M or Methuselah Prize (with the 
lofty goal of extending human life), have 
spoken at the event. “If you get the public 
to cheer on scientists like they do runners 
during a marathon, you’ll get things mov-
ing,” says Marc Hodosh, Senior Advisor 
for the Archon X Prize for Genomics—
a competition to decode 100 human 
genomes in 10 days for less than $10,000 
a genome—and president of a new type of 
TED Talk devoted to health and medicine, 
TEDMED (http://www.tedmed.com/). 
Yet the prize movement is countered 
by skepticism. Can breakthroughs be 
predicted? And who can afford to finance 
their work up-front? Kathy Hudson, the 
Chief of Staff to NIH Director Francis Col-
lins, says that she and others at the NIH 
are sifting though potential complica-
tions to explore if prizes could work for 
them. “One of the challenging aspects 
for us, because we are such a large sup-
porter of biomedical research, is that 
if we were to have a prize mechanism, 
the people competing would also be our 
grantees. And there is something odd 
about that,” she says. “This is a serious 
thing to think about. What if we had two 
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grantees competing for a prize and one 
grantee had more funding from us.” She 
adds, “I understand the Gates Founda-
tion is considering prizes, and they are in 
an analogous position.” The NIH is also 
grappling with what makes an appropri-
ate prize target and what metric could be 
used to evaluate the solution. Nonethe-
less, Hudson says the prize concept is 
intriguing, “Francis [Collins] has been giv-
ing it thought and the Office of the Direc-
tor has been giving it thought.”
Likewise, Eva Guinan, a transplant 
physician at Harvard Medical School 
who is guiding the contest for solutions 
for type 1 diabetes, says, “It was clear 
from the beginning that this would be 
challenging. Right now, we’re just set-
ting off on an academic journey to 
explore what parts of this approach 
are useful in our communities and 
what parts aren’t. We’ve joined up 
with several companies, including Top-
Coder and  InnoCentive, and Harvard 
Catalyst was fortunate enough to be 
awarded supplementary ARRA [Ameri-
can Recovery and Reinvestment Act] 
funding to study how this sort of initia-
tive is best implemented, starting with 
a focus on novel approaches to type 1 
diabetes.”
Solutions Wanted
Two scientists at the pharmaceutical 
company Eli Lilly dreamed up InnoCen-
tive in 2001 as a way to use the web to 
outsource problems that weren’t being 
solved in-house. InnoCentive branched 
off from Eli Lilly in 2005 and expanded 
its services to a variety of industries. 
Solutions sought range from creat-
ing algorithms and software to identify 
gene networks from microarray data to 
new strategies for treating autoimmune 
disease. The firm operates by helping 
organizations, called “seekers,” to post 
challenges on the firm’s website for a 
fee. Registered “solvers” then compete 
to win cash prizes offered by the “seek-
ers.” If the problem is solved, InnoCen-
tive earns a finder’s fee. The company 
now also offers consulting services and 
software that enables businesses to post 
challenges within their organization.
Advertising competitions allows orga-
nizations to turn to anyone with internet 
access for answers. “Crowdsourcing,” 
the term for this phenomenon, may be 
new, but the concept is centuries old. In 
1714, the British Parliament held a con-
test to find a way to accurately determine 
a ship’s longitude. A clockmaker took 
home the largest award for inventing the 
marine chronometer. A similarly anony-
mous 25-year-old airmail pilot, Charles 
Lindbergh, won the $25,000 Orteig 
Prize in 1927 for flying nonstop between 
New York City and Paris, beating famed 
pilots.
“There are more than enough people 
who are bright and passionate, and you 
want to tap these people at the right time 
so they can work on these important 
problems,” says Spradlin. About 60% of 
the 190,000 registered solvers currently 
competing for InnoCentive prizes have 
a Masters degree or a PhD. More than 
40% of registered solvers come from 
Brazil, Russia, India, and China; 30% 
from the US; and the remainder from 
over 150 other countries. Regarding Har-
vard’s type 1 diabetes challenge, Guinan 
says, “You might imagine that some-
one who works with disenfranchised 
children could have a good idea about 
how to motivate youths to do mundane 
tasks like take insulin. Maybe some-
one who works in museum design, who 
knows how to facilitate the way people 
walk through an exhibit, might be able 
to design something that will help indi-
viduals whose activities are impeded by 
diabetic neuropathy.” She says, “We are 
seeking new ways to bring scientists to 
different tables; new ways to expose the 
ideas of scientists who are at unempow-
ered spots in the academic hierarchy; 
and we are trying to figure out how to get 
ideas from people who don’t have the 
resources to enact their ideas.”
Experts stand to gain from crowd-
sourcing as well. Harvard neurologist 
Seward Rutkove competed in an Inno-
Centive challenge seeking a way to track 
the progression of amyotrophic lateral 
sclerosis (ALS), or Lou Gehrig’s disease, 
because he was researching that topic 
already. He won $50,000 for presenting 
his solution and was prepared to stop 
there, rather than reach for the $1 mil-
lion prize to demonstrate the ability of 
treatment to ward off an ALS-like dis-
ease in mice. Yet he learned something 
that changed his mind—access to the 
relevant strain of mice. “If they’ll provide 
me with free animals, I’ll enter because 
even if I don’t win the prize I might get 
a paper out of it,” he says. “I do have 
this vague idea I’ve been cooking for a 
couple of years and now I have a chance 
to see if it comes true or not.” Access 
to genome sequence data for 250 lines 
of corn may entice geneticists to enter 
InnoCentive’s upcoming Corn Genomics 
Challenge for a computationally derived 
indicator of the plant’s performance in 
fields with imperfect growing conditions. 
And top competitors in the upcom-
ing Healthcare X Prize—which seeks a 
strategy to improve healthcare value by 
>50% in a 10,000-person community 
over 3 years—will be able to try out their 
solutions on real populations.
The Thrill of the Chase
Bigger prizes require larger invest-
ments from both seekers and solvers. 
Thus, the stakes are high at the X Prize 
Foundation, where prizes range from 
$1 to $30 million, and challenges take 
years to formulate. Harvard geneticist 
George Church helped to sculpt the 
rules and ethics guidelines for the $10 
million Archon X Prize for Genomics. 
Having been involved with the Human 
Genome Project, he was familiar with 
complications, such as privacy issues, 
inherent to the field. Biological chemist 
Steven Benner is stumbling over other 
matters as he and his team pursue the 
prize. “We spent the first year asking 
about the criteria we needed to meet 
for their challenge. Now we have techni-
cal questions, like will the samples be 
from sperm, blood, or tissue?” And, the 
Foundation has yet to define how they 
will validate contestants’ data. Church, 
who has stepped down from the X Prize 
committee to compete, says stoically, 
“This prize has a way of warping the 
field.” Benner questions if the field is 
being warped in the right direction. He 
says, “The winner of the Archon Prize 
will need to solve the problem in genome 
sequencing that appears to have the 
least value—sequencing the repeating, 
noncoding regions.” He says genome-
related questions that help to tackle 
disease might do more public good, as 
would a solution to the problem of how 
to interpret sequences. “The pink ele-
phant of genomics is that we know little 
more about Craig Venter now that we 
have his DNA, than we knew before.”
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Smaller prizes posted by InnoCen-
tive may be fraught with fewer com-
plications. A $20,000 challenge seeks 
a method to optimize tags for protein 
expression in plants; a $150,000 chal-
lenge seeks a stable protein that mim-
ics a trimeric HIV envelope protein; and 
a $30,000 challenge calls for a method 
to characterize functional groups on the 
outer surface of keratin fibers like hair 
and wool. A solver presenting a theo-
retical solution to this problem stands 
to win $15,000. This partial prize might 
please skeptics like biochemist Kary 
Mullis, winner of the 1993 Chemistry 
Nobel Prize for inventing PCR, who 
fears that not all innovators have money 
jingling in their pockets. Mullis says, 
“Prizes are nice but they don’t help us 
recognize an unaccomplished person in 
the very beginning.” Instead, he says, “If 
I were in a situation with an extra billion 
hanging around and I wanted to pro-
mote innovation, I would consider giving 
a prize, not for developing something, 
but for writing something that describes 
a potential development...That early 
phase between the creation of an idea 
and the defining experiment is the most 
treacherous part of an adventure.”
Harvard economist Michael Kre-
mer explores alternatives to incentive 
prizes—other means of providing the 
“pull” that is lacking in scientific fields 
not backed by a market. For example, 
biotech and pharmaceutical compa-
nies avoid developing drugs for treating 
neglected diseases because of the risk 
that they may not recoup their costs 
when low-income individuals cannot 
afford the treatments they offer. Kre-
mer says, “In the US, the NIH provides 
the ‘push’ by putting money up front for 
science. And in some cases, such as in 
cancer research, pharmaceutical com-
panies provide the ‘pull.’ What’s miss-
ing out there for neglected diseases 
and basic science is the ‘pull’ com-
ponent.” Kremer and his colleagues 
have convinced the Gates Foundation 
and four countries to put forth $1.5 
billion for an alternative incentive, an 
Advanced Market Commitment (AMC) 
for neglected diseases that will reward 
the winning team with a purchase order 
for a certain number of pneumococcal 
vaccines at a set price. Kremer adds 
that fundamental research may not 
benefit from AMCs because the results 
may not be marketable.
Fame and Fortune
Teams often manage to raise money 
as they compete and gain popularity. 
Indeed, the X Prize Foundation has 
succeeded in making science glam-
orous. Multiple television companies 
have approached the X Prize Founda-
tion in the hopes of documenting the 
$10 million Automotive X Prize for an 
economically viable and energy-effi-
cient car. And Google cofounder Larry 
Page, CNN’s Larry King, and theoreti-
cal physicist Stephen Hawking have 
joined the “Genome 100,” a group that 
will have their genomes sequenced, 
and will in the meantime be spokes-
men for the Archon X Prize in Genom-
ics. “Ultimately, our job is to be good to 
the teams. We make them heroes glob-
ally, so that they can raise money from 
benefactors and investors. We pick a 
breakthrough that is audacious, practi-
cal, and of value to humanity,” says X 
Prize Foundation CEO Diamandis. “We 
want the world to recognize that these 
are heroes who strive to achieve some-
thing of value. During the course of the 
Archon X prize, the public will really 
start to grasp the concept of personal-
ized genome sequencing, and they will 
want to participate.”
“This is about a celebration of science 
and the people who solve problems. 
Today our society celebrates entertain-
ers and athletes. There’s nothing wrong 
with that, but it is a little out of whack. We 
should be celebrating scientists, engi-
neers, and innovators. It’s about chang-
ing our culture,” says TEDMED President 
and X Prize Senior Advisor Marc Hodosh. 
“Organizations are realizing they need to 
innovate and that they need to think dif-
ferently about that process. We like to 
say, a crisis is a terrible thing to waste. 
We think organizations can come out 
stronger from this economic crisis by 
doing two kinds of research, by tapping 
their internal and external talent pools,” 
says InnoCentive CEO Spradlin. “This 
past year, we’ve found ourselves in a 
weird position of leadership where orga-
nizations are looking to us and changing 
the way they think about innovation.”
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